CL2013003795A1 -
Pharmaceutical combination comprising an anti-erbb3 antibody and paclitaxel; use of the pharmaceutical combination to prepare a medicament useful for the treatment of refractory or platinum resistant gynecological cancer in a human patient.
- Google Patents
Pharmaceutical combination comprising an anti-erbb3 antibody and paclitaxel; use of the pharmaceutical combination to prepare a medicament useful for the treatment of refractory or platinum resistant gynecological cancer in a human patient.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Merrimack Pharmaceuticals IncfiledCriticalSanofi Sa
Publication of CL2013003795A1publicationCriticalpatent/CL2013003795A1/en
CL2013003795A2011-06-302013-12-30
Pharmaceutical combination comprising an anti-erbb3 antibody and paclitaxel; use of the pharmaceutical combination to prepare a medicament useful for the treatment of refractory or platinum resistant gynecological cancer in a human patient.
CL2013003795A1
(en)
Pharmaceutical combination comprising an anti-erbb3 antibody and paclitaxel; use of the pharmaceutical combination to prepare a medicament useful for the treatment of refractory or platinum resistant gynecological cancer in a human patient.
Pharmaceutical composition comprising (-) - carvone, (+) - carvone, trans-geraniol and at least one component chosen from essential oils for use in the treatment and prevention of viral diseases.
cancer treatment method, method of enhancing the therapeutic effectiveness of an anticancer drug, pmo1183 or a pharmaceutically acceptable salt thereof, use thereof and kit for use in cancer treatment
Pharmaceutical compositions and use to prepare a drug for the treatment of obesity, related metabolic disorders and addiction to psychoactive substances
Composition comprising chemotherapy with paclitaxel and carboplatin and an anti-clusterine oligonucleotide; use of the composition for the treatment of a human patient suffering from lung cancer.
Compounds derived from difluoro-hexahydro-cyclopentaoxacinyls and difluoro-hexahydro-benzooxacinyls, bace 1 inhibitors; pharmaceutical composition; and its use in the treatment of diseases with elevated levels of beta-amyloid, such as Alzheimer's disease